Back to results
US 2026/0053750 A1Published application
Inhalable compositions of cdk9 inhibitors
AssigneesThe Regents of the University of California, Tesio Pharmaceuticals, Inc.
InventorsMatthew OWEN, Tom YARBROUGH, Dominik HAUDENSCHILD, Jasper YIK, Gang-Yu LIU, Ching-Hsien CHEN, Reen WU, Lark COFFEY, Mei-chang KUO
Life of this patent
Estimating the term…
Abstract
The present disclosure describes a formulation for the delivery of CDK9 inhibitors.
Claims35
A microparticle composition comprising a plurality of microparticles, wherein each microparticle comprises:
- a hydrophobic amino acid or a hydrophobic peptide, or combinations thereof;
- a lipid;
- and
- a cyclin-dependent kinase 9 (CDK9) inhibitor.
1 more element
3-6. (canceled)
(canceled)
12-13. (canceled)
15-18. (canceled)
20-21. (canceled)
(canceled)
A method of preparing a plurality of particles for a microparticle composition, the method comprising:
- sonicating a first reaction mixture comprising L-isoleucine and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), water, and ethanol, wherein the L-isoleucine and DPPC are present in a ratio of about 9:1 (w/w), and wherein the ethanol:water ratio is about 70:30 (v/v), to prepare a 0.3% (w/v) feed mixture;
- applying the feed mixture to a microfluidic piezo array to form a spray of micronized droplets;
- and
- drying the droplets to afford the plurality of particles.
1 more element
A liquid composition comprising:
- a citric acid buffer having a pH of from 2 to 7;
- and
- a cyclin-dependent kinase 9 (CDK9) inhibitor.
33-35. (canceled)
42-48. (canceled)
(canceled)
Dependencies are inferred from the claim text.